| Date Filed | Type | Description |
| 10/12/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/16/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/14/2023 |
4
| Delfini Lisa (CFO) has filed a Form 4 on Trevi Therapeutics, Inc.|
Txns:
| Sold 682 shares
@ $2.36, valued at
$1.6k
Exercised 2,292 options to buy
@ $0.511, valued at
$1.2k
|
|
| 08/11/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2 CANAL trial of chronic cough in patients with idiopathic pulmonary fibrosis published in NEJM Evidence Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., August 10, 2023 – Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis , other chronic cough indications, and prurigo nodularis, today announced financial results for the quarter ended June 30, 2023, as well as provided business updates. ..." |
|
| 07/12/2023 |
4
| Delfini Lisa (CFO) has filed a Form 4 on Trevi Therapeutics, Inc.|
Txns:
| Sold 687 shares
@ $2.34, valued at
$1.6k
Exercised 2,292 options to buy
@ $0.511, valued at
$1.2k
|
|
| 06/30/2023 |
4
| Mathers Edward T (Director) has filed a Form 4 on Trevi Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $2.27, valued at
$68.1k
|
|
| 06/30/2023 |
4
| Cassella James V (Director) has filed a Form 4 on Trevi Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $2.27, valued at
$68.1k
|
|
| 06/30/2023 |
4
| Heffernan Michael Thomas (Director) has filed a Form 4 on Trevi Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $2.27, valued at
$68.1k
|
|
| 06/30/2023 |
4
| Meeker David P (Director) has filed a Form 4 on Trevi Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $2.27, valued at
$68.1k
|
|
| 06/30/2023 |
4
| Colangelo Dominick (Director) has filed a Form 4 on Trevi Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $2.27, valued at
$68.1k
|
|
| 06/30/2023 |
4
| VANLENT ANNE (Director) has filed a Form 4 on Trevi Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $2.27, valued at
$68.1k
|
|
| 06/29/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 06/29/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 06/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/14/2023 |
8-K
| Quarterly results |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/16/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/15/2023 |
4
| Delfini Lisa (CFO) has filed a Form 4 on Trevi Therapeutics, Inc.|
Txns:
| Sold 892 shares
@ $1.7532, valued at
$1.6k
Exercised 2,291 options to buy
@ $0.511, valued at
$1.2k
|
|
| 03/08/2023 |
4
| Simon Farrell (Chief Commercial Officer) has filed a Form 4 on Trevi Therapeutics, Inc.|
Txns:
| Exercised 18,750 options to buy
@ $0.511, valued at
$9.6k
|
|
| 02/14/2023 |
SC 13G/A
| Venrock Healthcare Capital Partners II, L.P. reports a 10% stake in Trevi Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Fairmount Funds Management LLC reports a 9.9% stake in TREVI THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 5% stake in TREVI THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 10% stake in Trevi Therapeutics, Inc. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|